PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Oct 17, 2017

byncaipen

Biomanufacturing | Transplants

Scientific Update for Diabetes, Kidney Ischemia, Liver Perfusion, Retinal Cell Replacement, Monoclonal Antibody Production and Immune Cell Cryopreservation Recovery

Belpre, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) is pleased to provide a scientific update to its stockholders. The Company is exploring the following areas for the use...Read more

May 24, 2017

byncaipen

Ophthalmology | Transplants

ProtoKinetix Completes First Year of Trials on Retinal Replacement Therapy Using AAGP®

About ProtoKinetix, Incorporated ProtoKinetix, Incorporated (OTC: PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) today announces that it has completed the first year of retinal replacement therapy trials on animals and the...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.